MASSDEVICE ON CALL — A study of pacemaker usage confirmed what most medical device makers already know all too well – the U.S. cardiac rhythm management market just isn’t what is used to be.
Stagnancy in the CRM arena has been an anchor weighing down many of the largest medical device makers, including rival medical device makers St. Jude Medical (NYSE:STJ) and Boston Scientific (NYSE:BSX), both of which have lamented the sluggish market and its impact on their quarterly earnings.
Pacemaker use increased 56% between 1993 and 2009, but most of that occurred in the 1990s and has leveled off since hitting a growth peak in 2001, according to a Reuters Health report.
Meanwhile, pacemaker patients have gotten older and sicker, the median age of a dual-chamber pacemaker recipient rising from 73 to 75 years old and exhibiting more co-morbidities than in 1993, according to the newswire.
"The overall market is down in the U.S., but we do see that implant volume is growing," Ishrak said during a conference call with investors last month. "We were pleased to see relative sequential stability in the market."
Romney plan could double healthcare costs for families, study says
A study released by liberal advocacy group Families USA reports that families could end up paying almost double for health insurance in plans proposed by Mitt Romney.
Is the GOP losing favor on healthcare?
New polls find President Barack Obama’s healthcare reform act has gained significantly in popularity and that voters belief the incumbent president can do a better job managing the future of U.S. healthcare.
Hospitals bite back against HHS warning on EMR fraud
The American Hospital Assn. charged back against warnings from Health & Human Services Secretary Kathleen Sebelius, arguing that the federal Medicare program needs to clean up its own coding before accusing care providers of deliberately misusing codes.
FDA takes over some clinical trial reporting
The Dept. of Health & Human Services passed some of the responsibility of monitoring and reporting clinical trials over to the FDA, according to an agency notice.